Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
IgA nephropathy is the most common type of primary glomerulonephritis and might caused by
deposition of immune complex containing IgA in mesangium and causing local immune activation.
Hydroxychloroquine reduces the activation of dendritic cells and the inflammatory process and
showed the potential effect of treatment of patients with IgA nephropathy.
The investigators study will recruite IgA nephropathy patients with proteinuria range from
0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were
treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded
every two months and total four months. Then, the drug will be stopped for two months for
observation of change of proteinuria.